Other OTC • Healthcare • Biotechnology • US • USD
Ayala Pharmaceuticals, Inc. (ADXS) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 6 recommend buying, 2 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
